Median OS was superimposable in patients who did and did not receive AFP (8.1 months vs. 12.5 months);Poor fitness (HR 4.21) and TP53 mutation (HR 3.06);No significant differences in IFD’s incidence, OS, proportion of patients proceeding to HCT or experiencing relapse according to AFP use.Concurrent VEN dose reduction did not compromise AML outcomes. Here, TP53 is linked to acute myeloid leukemia.